RPG Life Sciences’ subsidiary, RPG Active Pharma, has signed a deal to acquire Raghava Life Sciences’ API business for ₹135 crore. The transaction includes a 300 KL capacity plant and 22 commercialized APIs, aiming to scale the company's production footprint. Investors should track the integration progress, as the company works to balance rapid inorganic expansion with operational efficiency.
RPG Life Sciences has announced that its subsidiary, RPG Active Pharma, has entered into a slump-sale agreement to acquire the API and intermediate business of Raghava Life Sciences. The deal is valued at ₹135 crore and is expected to close within 30 days of the announcement. This acquisition marks a significant step in the company's plan to expand its chemical and API manufacturing operations in India.
Strategic Consolidation
This purchase follows a clear consolidation strategy. RPG Life Sciences recently formed its subsidiary, RPG Active Pharma, which secured a ₹243.33 crore investment from the private equity firm InvAscent for a 40% stake. The company previously spent ₹80 crore to acquire Actis Generics. Together, these moves show a shift toward scaling the API platform through acquisitions rather than relying solely on internal growth. By pooling these assets under the new subsidiary, the management aims to improve operational leverage and provide a more comprehensive, end-to-end service model for global customers.
Assets and Capacity
The acquisition brings a WHO-GMP and EU-GMP approved facility in Visakhapatnam, which adds 300 KL of installed capacity to the company's network. Beyond the infrastructure, the company gains 22 commercialized API molecules and 7 products currently in development. These additions are designed to help the company capture a larger share of the pharmaceutical supply chain.
Risks and Monitorables
While the expansion adds capacity, it comes with operational and financial considerations. Analysts have noted that the acquisition valuation appears relatively high, with some estimates placing it over 7 times the revenue of Raghava's API unit. Successfully integrating these new facilities while maintaining the company’s Q1 FY27 EBITDA margin of 24.5% will be a key challenge for management. Investors should also be aware of execution risks involved in commercializing the 7 pipeline molecules.
Furthermore, the company has dealt with past operational disruptions, such as a fire at its facility in FY2026, which highlights the importance of maintaining strict safety standards and consistent supply chain management during this rapid expansion phase. The primary monitorable for shareholders will be whether the company can integrate these assets without hurting its profitability, and how it plans to manage the transition of these new businesses into its existing framework.